US sales of FOSRENOL for the year to December 31, 2007 were up 54% to US$62.1 million compared to the same period in 2006 (2006: US$40.2 million). FOSRENOL's average market share of the US phosphate binder market increased from 8.5% in 2006 to 8.6% in 2007. The increase in product sales is due to a small wholesaler stocking increase in 2007 compared to significant wholesaler de-stocking of initial launch stocks in 2006, the continued shift to the 1 gram strength tablet launched in 2006, partially offset by higher sales deductions in 2007 compared to the same period in 2006 (relating to a one-off provision made in 2007 for returns of the 750 gram dose).
DYNEPO - Anaemia associated with Chronic Kidney Disease ("CKD")
DYNEPO was launched in March 2007 in Germany and later in the year in the UK, France, Italy and Ireland with sales for 2007 reaching US$14.2 million.
CARBATROL - Epilepsy
US prescriptions for CARBATROL for the year to December 31, 2007 were down 5% compared to the same period in 2006. This was primarily due to a comparable decline in the US extended release carbamazepine prescription market; CARBATROL's average market share remained constant.
Sales of CARBATROL for the year to December 31, 2007 were US$72.3 million, an increase of 6% compared to the same period in 2006 (2006: US$68.3 million). Product sales increased despite the decrease in prescriptions, due to a sales price increase in April 2007 and restocking to normal levels, partially offset by higher sales deductions.
Patent litigation proceedings relating to CARBATROL are ongoing. Further information can be found in our filings with the SEC, including our Annual Report on Form 10-K for the year to December 31, 2007.
XAGRID - Thr
|SOURCE Shire plc|
Copyright©2008 PR Newswire.
All rights reserved